Little House Capital’s Moderna MRNA Stock Holding History

Little House Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,089	Closed	-$329K	–	122
2024 Q1	$329K	Buy	+3,089	New	+$311K	0.11%	113

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Little House Capital's MRNA Position: Q2 2024 in Review

Little House Capital sold out of Moderna (MRNA) in Q2 2024, closing a stake of 3,089 shares — an estimated $329K sold.

Little House Capital first reported a position in MRNA in Q1 2024 and held it in 1 quarter. The position peaked at $329K in Q1 2024. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

Little House Capital reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
Little House Capital sold 3,089 Moderna shares in Q2 2024, an estimated $329K.
Little House Capital first reported a position in Moderna in Q1 2024 and held it in 1 quarter.
Little House Capital's Moderna position peaked at $329K in Q1 2024.
954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Little House Capital's 13F filing for Q2 2024, filed 2 Aug 2024.